Intellia's (NTLA) Q2 Loss Wider Than Expected, Revenues Beat

This article was originally published on Nasdaq

Intellia Therapeutics NTLA incurred a loss of $1.33 per share in second-quarter 2022, wider than the year-ago quarter’s loss of $1.01 and the Zacks Consensus Estimate of a loss of $1.31.

Responses